[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371813-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371813-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","progression-of-drug-resistance-or-multiple-primary-lung-cancer-a-case-report-and-literature-review","Progression of drug resistance or multiple primary lung cancer - a case report and literature review","","Mesenchymal–epithelial transition factor (MET) exon 14 skipping alterations are rare non-small cell lung cancer mutations linked to aggressive behavior and poor outcomes. The case describes advanced left upper lung adenocarcinoma with a MET14 mutation that responded to crizotinib, followed by enlargement of the right upper lung lesion. Biopsy and genetic testing identified an EGFR L858R mutation, supporting multiple primary lung cancer. The patient received almonertinib plus crizotinib without surgery or local therapy, achieving sustained stability and overall survival beyond 53 months.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/progression-of-drug-resistance-or-multiple-primary-lung-cancer-a-case-report-and-literature-review/371813/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/progression-of-drug-resistance-or-multiple-primary-lung-cancer-a-case-report-and-literature-review/371813.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-22","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What genetic alterations are central to this case?","Question",{"text":63,"@type":64},"The left upper lung adenocarcinoma carried a MET exon 14 skipping alteration (MET14). After progression of the right upper lung lesion, biopsy confirmed an EGFR L858R mutation, indicating multiple primary lung cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the disease respond after initial crizotinib treatment?",{"text":68,"@type":64},"First-line crizotinib produced a marked reduction in the primary left upper lung lesion size.",{"name":70,"@type":61,"acceptedAnswer":71},"Why was multiple primary lung cancer considered instead of MET inhibitor resistance progression?",{"text":72,"@type":64},"Imaging later showed enlargement with increased solid components in the right upper lung lesion, and genetic testing demonstrated a different driver mutation (EGFR L858R) rather than changes consistent with MET-pathway–driven progression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371813,1790320068,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":138,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":12,"update_tm":142,"read_time":143,"preview_page_count":33,"preview_urls":144},4398046744996,"Case report  \n759  \nProgression of drug resistance or multiple primary lung cancer: a case report and literature review of a patient with mesenchymal–epithelial transition factor exon 14 skipping alterations lung adenocarcinoma  \nLiang Gong* , Lihang Zhou* , Pan Yang* , Fu Xiong, Xin Li and Chunlan Tang  \nMesenchymal–epithelial transition factor (MET) exon  \n14 skipping alterations are rare mutations in non-smallcell lung cancer, associated with high malignancy and poor prognosis. This article presents a case of a patient diagnosed with advanced left upper lung adenocarcinoma characterized by a MET14 skipping mutation. Following first-line treatment with crizotinib, there was a significant reduction in the size of the primary lesion; however, during the course of treatment, an increase in size and prominence of solid components were observed in the right upper lung lesion. A biopsy and subsequent genetic testing revealed an epidermal growth factor receptor L858R mutation in the right upper lung adenocarcinoma, indicating the presence of multiple primary lung cancers. The patient opted against surgical intervention and local treatments, choosing instead a combination therapy regimen that included almonertinib and crizotinib. This treatment approach led to a significant reduction in the  \nsize of the right upper lung lesion. The patient’s condition has remained stable without any signs of progression, resulting in an overall survival duration exceeding 53 months. Anti-Cancer Drugs 36: 759–763 Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.  \nAnti-Cancer Drugs 2025, 36:759–763  \nKeywords: almonertinib, crizotinib, MET exon 14 skipping alterations, multiple primary lung cancer  \nDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Army Medical University, Chongqing, China  \nCorrespondence to Chunlan Tang, PhD, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Army Medical University, 30 Gaotan Yanzheng Street, Chongqing 400038, China  \nTel: +86 02368765314; e-mail: [chunlantangok@tmmu.edu.cn](chunlantangok@tmmu.edu.cn)  \n*Liang Gong, Lihang Zhou, and Pan Yang contributed equally to the writing of this article.  \nReceived 10 April 2025 Revised form accepted 10 April 2025.  \nThe mesenchymal–epithelial transition factor (MET) gene, also referred to as c-MET, is a proto-oncogene situated on the long arm of human chromosome 7 atthe locus 7q21-31 . Mutations involving mesenchymal– epithelial transition factor exon 14 skipping alterations (METex14) lead to the loss of the transmembrane domain in the resulting abnormal protein. This alteration impairs the ubiquitination of c-MET protein, thereby increasing its stability and reducing its degradation rate. Consequently, this results in persistent activation of MET signaling pathways and ultimately contributes to tumorigenesis [1] . Individuals with METex14 tend to be older, have a history of smoking, and exhibit a poor response to both chemotherapy and immunotherapy [2,3] . Consequently, the development of tyrosine kinase inhibitors (TKIs) targeting MET has emerged as a prominent area of research. These inhibitors function by blocking MET activity, which in turn prevents the phosphorylation of downstream kinases. This mechanism effectively halts downstream signal transduction and regulates key processes such as tumor cell proliferation, metastasis, and angiogenesis.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBYNC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nCurrently, MET inhibitors have received approval for first-line treatment specifically addressing METex14 . The evolution of targeted drug resistance is characterized by several mechanisms including gene amplific","cbCairQIjYc2Ddcy","https://ap.wps.com/l/cbCairQIjYc2Ddcy","pdf",801096,"English","# Case report\n## Clinical presentation and diagnosis\n## Treatment course and response\n## Genetic testing and differential consideration\n## Outcome and follow-up\n# Background and literature review","[{\"question\":\"What genetic alterations are central to this case?\",\"answer\":\"The left upper lung adenocarcinoma carried a MET exon 14 skipping alteration (MET14). After progression of the right upper lung lesion, biopsy confirmed an EGFR L858R mutation, indicating multiple primary lung cancers.\"},{\"question\":\"How did the disease respond after initial crizotinib treatment?\",\"answer\":\"First-line crizotinib produced a marked reduction in the primary left upper lung lesion size.\"},{\"question\":\"Why was multiple primary lung cancer considered instead of MET inhibitor resistance progression?\",\"answer\":\"Imaging later showed enlargement with increased solid components in the right upper lung lesion, and genetic testing demonstrated a different driver mutation (EGFR L858R) rather than changes consistent with MET-pathway–driven progression.\"}]","Progression of drug resistance or multiple primary lung cancer - a case report and literature review | PDF",1790192929,13,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3925431618ac09f6501d0331f1989912.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85c92de0e1d51d6304ec7bee8ab713b2.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76c3eaaa3572b51298841081bd5c5c97.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb56ff9b342a7b9f065b5fd4bbc88890.webp",980,1306]